BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 24764162)

  • 21. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer.
    Hapuarachchige S; Huang CT; Donnelly MC; Bařinka C; Lupold SE; Pomper MG; Artemov D
    Mol Pharm; 2020 Jan; 17(1):98-108. PubMed ID: 31840521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors.
    Lütje S; Heskamp S; Franssen GM; Frielink C; Kip A; Hekman M; Fracasso G; Colombatti M; Herrmann K; Boerman OC; Gotthardt M; Rijpkema M
    Theranostics; 2019; 9(10):2924-2938. PubMed ID: 31244933
    [No Abstract]   [Full Text] [Related]  

  • 24. Biodistribution of monoclonal IgG1, F(ab')2, and Fab' in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies.
    Holton OD; Black CD; Parker RJ; Covell DG; Barbet J; Sieber SM; Talley MJ; Weinstein JN
    J Immunol; 1987 Nov; 139(9):3041-9. PubMed ID: 3499463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of IgG and F(ab')2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposes.
    van Schaijk FG; Boerman OC; Soede AC; McBride WJ; Goldenberg DM; Corstens FH; Oosterwijk E
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1089-95. PubMed ID: 15902440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of tumour mass and circulating antigen on the biodistribution of 111In-labelled F(ab')2 fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts.
    Perälä-Heape M; Vihko P; Laine A; Heikkilä J; Vihko R
    Eur J Nucl Med; 1991; 18(5):339-45. PubMed ID: 1936042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts.
    Sharkey RM; Motta-Hennessy C; Pawlyk D; Siegel JA; Goldenberg DM
    Cancer Res; 1990 Apr; 50(8):2330-6. PubMed ID: 2180566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting of liver metastases of colorectal cancer with IgG, F(ab')2, and Fab' anti-carcinoembryonic antigen antibodies labeled with 99mTc: the role of metabolism and kinetics.
    Behr T; Becker W; Hannappel E; Goldenberg DM; Wolf F
    Cancer Res; 1995 Dec; 55(23 Suppl):5777s-5785s. PubMed ID: 7493346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
    van Dijk J; Zegveld ST; Fleuren GJ; Warnaar SO
    Int J Cancer; 1991 Jul; 48(5):738-43. PubMed ID: 1830033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies?
    Watanabe R; Hanaoka H; Sato K; Nagaya T; Harada T; Mitsunaga M; Kim I; Paik CH; Wu AM; Choyke PL; Kobayashi H
    J Nucl Med; 2015 Jan; 56(1):140-4. PubMed ID: 25500827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.
    Viola-Villegas NT; Sevak KK; Carlin SD; Doran MG; Evans HW; Bartlett DW; Wu AM; Lewis JS
    Mol Pharm; 2014 Nov; 11(11):3965-73. PubMed ID: 24779727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The binding parameters of radiolabelled monoclonal F (ab')2 and Fab' fragments relative to immunoglobulin G in reactions with surface-bound antigens.
    Fjeld JG; Michaelsen TE; Nustad K
    Eur J Nucl Med; 1992; 19(6):402-8. PubMed ID: 1618231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive Evaluation of CD20 Expression Using
    Kang L; Li C; Rosenkrans ZT; Engle JW; Wang R; Jiang D; Xu X; Cai W
    J Nucl Med; 2021 Mar; 62(3):372-378. PubMed ID: 32826320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody.
    Carter T; Sterling-Levis K; Ow K; Doughty L; Hattarki M; Shapira D; Hewish D; Kortt AA; Russell PJ
    Cancer Immunol Immunother; 2004 Jun; 53(6):533-42. PubMed ID: 14722669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.
    Schneider DW; Heitner T; Alicke B; Light DR; McLean K; Satozawa N; Parry G; Yoo J; Lewis JS; Parry R
    J Nucl Med; 2009 Mar; 50(3):435-43. PubMed ID: 19223400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients.
    Murray JL; Rosenblum MG; Zhang HZ; Podoloff DA; Kasi LP; Curley SA; Chan JC; Roh M; Hohn DC; Brewer H
    Cancer; 1994 Feb; 73(3 Suppl):850-7. PubMed ID: 8306270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.